[EN] A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN<br/>[FR] MÉDICAMENT DESTINÉ AU TRAITEMENT D'UNE INFECTION MYCOBACTÉRIENNE, CARACTÉRISÉ PAR LA COMBINAISON D'UN INHIBITEUR DE CYTOCHROME BC1 AVEC DE LA CLARITHROMYCINE OU DE L'AZITHROMYCINE
申请人:SHIONOGI & CO
公开号:WO2022119899A1
公开(公告)日:2022-06-09
A medicament characterized in that (A) a compound represented by formula (I):, or its pharmaceutically acceptable salt, wherein R1, R2, R3and R4are each independently hydrogen atom, halogen, hydroxy, cyano, substituted or unsubstituted alkyl or the like; R5is a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl or the like; R6, R7, R8and R9are each independently hydrogen atom, halogen or the like; X is CH or N; Y is CH or N; R10is each independently halogen, hydroxy, cyano, substituted or unsubstituted alkyl or the like; m is 0, 1, 2, 3 or 4; R11is halogen, hydroxy, cyano, substituted or unsubstituted alkyl or the like; R12is each independently halogen, hydroxy, cyano or the like; n is 0, 1, 2, 3 or 4; is combined with (B) clarithromycin or its pharmaceutically acceptable salt, or azithromycin or its pharmaceutically acceptable salt; and (C) clofazimine, or its pharmaceutically acceptable salt.
一种药物,其特点在于(A)化合物由式(I)表示,或其药学上可接受的盐,其中R1、R2、R3和R4分别独立地为氢原子,卤素,羟基,
氰基,取代或未取代的烷基或类似物;R5为氢原子,卤素,
氰基,取代或未取代的烷基或类似物;R6、R7、R8和R9分别独立地为氢原子,卤素或类似物;X为CH或N;Y为CH或N;R10分别独立地为卤素,羟基,
氰基,取代或未取代的烷基或类似物;m为0,1,2,3或4;R11为卤素,羟基,
氰基,取代或未取代的烷基或类似物;R12分别独立地为卤素,羟基,
氰基或类似物;n为0,1,2,3或4;与(B)
克拉霉素或其药学上可接受的盐,或
阿奇霉素或其药学上可接受的盐结合;以及(C)克罗法齐明或其药学上可接受的盐。